{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:18:38Z","timestamp":1786997918564,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Pharmaceutical Companies of Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.vaccine.2023.01.006","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T03:41:56Z","timestamp":1672890116000},"page":"1602-1610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan"],"prefix":"10.1016","volume":"41","author":[{"given":"Yumi","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Numaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4893-3526","authenticated-orcid":false,"given":"Kiichiro","family":"Toyoizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Le Gars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.006_b0005","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.15585\/mmwr.mm7034e1","article-title":"New COVID-19 cases and hospitalizations among adults, by vaccination status \u2014 New York, 3 May-25 July 2021","volume":"70","author":"Rosenberg","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.01.006_b0010","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard, https:\/\/covid19.who.int\/; [accessed 1 June 2022]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0015","unstructured":"McGill COVID19 Vaccine Tracker Team. COVID19 vaccine tracker Japan, https:\/\/covid19.trackvaccines.org\/country\/japan\/; 2021 [accessed 3 December 2021]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0020","unstructured":"Pharmaceuticals and Medical Devices Agency. Report on the deliberation results vaxzevria intramuscular injection, https:\/\/www.pmda.go.jp\/files\/000243208.pdf; 2021 [accessed 5 April 2022]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0025","unstructured":"Pharmaceuticals and Medical Devices Agency. Report on the deliberation results COVID-19 vaccine Moderna intramuscular injection, https:\/\/www.pmda.go.jp\/files\/000245381.pdf; 2021 [accessed 5 April 2022]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0030","unstructured":"Pharmaceuticals and Medical Devices Agency. Report on the deliberation results comirnaty intramuscular injection, https:\/\/www.pmda.go.jp\/files\/000245075.pdf; 2021 [accessed 5 April 2022]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0035","unstructured":"Latif AA, Mullen JL, Alkuzweny M, Tsueng G, Cano M, Haag E, et al. Japan variant report, https:\/\/outbreak.info\/location-reports?loc=JPN&dark=true&selected=Delta&selected=Alpha&selected=Beta&selected=Gamma; [accessed 23 February 2022]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.01.006_b0045","doi-asserted-by":"crossref","unstructured":"Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:2187-201. https:\/\/doi.org10.1056\/NEJMoa2101544.","DOI":"10.1056\/NEJMoa2101544"},{"key":"10.1016\/j.vaccine.2023.01.006_b0050","doi-asserted-by":"crossref","unstructured":"Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med 2022;386:847-60. https:\/\/doi.org10.1056\/NEJMoa2117608.","DOI":"10.1056\/NEJMoa2117608"},{"key":"10.1016\/j.vaccine.2023.01.006_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.006_b0060","doi-asserted-by":"crossref","unstructured":"Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med 2021;384:1824-35. https:\/\/doi.org10.1056\/NEJMoa2034201.","DOI":"10.1056\/NEJMoa2034201"},{"key":"10.1016\/j.vaccine.2023.01.006_b0065","unstructured":"Centers for Disease Control and Prevention (CDC). COVID-19. People with certain medical conditions. Updated 14 December 2021, https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html; 2021 [accessed 27 December 2021]."},{"key":"10.1016\/j.vaccine.2023.01.006_b0070","unstructured":"Stephenson KE, Le Gars M, Sadoff J, de Groot AM, Heerwegh D, Truyers C, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA 2021;325:1535-44. https:\/\/doi.org10.1001\/jama.2021.3645."},{"key":"10.1016\/j.vaccine.2023.01.006_b0075","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1016\/j.vaccine.2022.05.047","article-title":"Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials","volume":"40","author":"Sadoff","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.006_b0080","unstructured":"Janssen. COVID-19 vaccine Ad26.COV2.S VAC31518 (JNJ-78436735). Janssen's briefing materials: vaccines and related biological products advisory committee. https:\/\/www.fda.gov\/media\/152954\/download; 2021. [accessed 5 August 2022]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:43Z","timestamp":1759404223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0264410X23000063"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}